Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,757 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Major Depressive Disorders Clear all

Conditions: Major Depressive Disorder
Interventions: Antidepressant + Placebo, Antidepressant + Aripiprazole; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 28
States / cities: Beverly Hills, California • Burbank, California • National City, California + 25 more

Conditions: Major Depression
Interventions: Not listed
Lead sponsor: Steward St. Elizabeth's Medical Center of Boston, Inc.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Treatment-Resistant Major Depressive Disorder
Interventions: Psilocybin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Treatment Resistant Depression
Interventions: Synergy, Epidural cortical stimulation; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 21 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Depression
Interventions: Transcranial Direct Current Stimulation, Sham Transcranial Direct Current Stimulation; Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Major Depressive Disorder
Interventions: Heart rate variability biofeedback; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 27 Years
Enrollment: 252 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Depression - Major Depressive Disorder, Transcranial Alternating Current Stimulation
Interventions: Closed-loop tACS, Sham Comparator; Device
Lead sponsor: Pulvinar Neuro, LLC; Industry
Eligibility: 22 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Major Depressive Disorder
Interventions: Creatine monohydrate or placebo; Drug
Lead sponsor: Perry Renshaw; Other
Eligibility: 13 Years to 21 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Major Depressive Disorder
Interventions: Icalcaprant, Placebo for Icalcaprant; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Dothan, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 27 more

Conditions: Major Depressive Disorder, Depression
Interventions: 0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT); Drug
Lead sponsor: Yale University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Mild Cognitive Impairment, Major Depressive Disorder, Alzheimer's Disease
Interventions: es-citalopram, Memantine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 50 Years to 90 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Depressive Disorder, Major
Interventions: Vortioxetine 10 mg/day, Vortioxetine 20 mg/day, Fluoxetine 20 mg/day, Placebo; Drug · Other
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 42
States / cities: Dothan, Alabama • Tucson, Arizona • Little Rock, Arkansas + 37 more

Conditions: Major Depressive Disorder 1
Interventions: Pharmacogenetic testing; Genetic
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Any FDA Approved Antidepressant; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Depression - Major Depressive Disorder, Cannabis Use Disorder, Mental Disorder
Interventions: Amplification of Positivity - Cannabis Use (AMP-C); Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Major Depressive Disorder
Interventions: ALTO-100 PO Tablet; Drug
Lead sponsor: Alto Neuroscience; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Coral Gables, Florida • Jackson, Mississippi

Conditions: Transdiagnostic, Depression - Major Depressive Disorder, Anxiety, PTSD Symptoms, PTSD, Substance Use, Substance Use Disorder (SUD), OCD
Interventions: Psilocybin; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Major Depressive Disorder (MDD), Suicidal Ideation, Hospitalization in Children
Interventions: Transcranial Magnetic Stimulation, Transcranial Magnetic Stimulation Sham; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 14 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Major Depressive Disorder
Interventions: Intervention app, Control app; Device · Other
Lead sponsor: Big Health Inc.; Industry
Eligibility: 13 Years and older
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Major Depressive Disorder
Interventions: Desvenlafaxine Succinate Sustained-Release 10mg, Desvenlafaxine Succinate Sustained-Release 50 mg, placebo; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 682 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Encino, California • Newport Beach, California + 21 more

Conditions: Human Immunodeficiency Virus, Neurocognitive Impairment
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 25 Years to 61 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Major Depressive Disorder, Psychotic Disorders
Interventions: mifepristone, mifepristone matched placebo, mifepristone 600 mg, mifepristone 1200 mg; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 44
States / cities: Little Rock, Arkansas • Cerritos, California • Fountain Valley, California + 40 more

Conditions: Major Depressive Disorder, Bipolar Disorder, Mild Cognitive Impairment
Interventions: Observational assessment using functional near-infrared spectroscopy (fNIRS), a noninvasive, portable brain imaging tool that measures changes in brain blood flow and oxygen levels.; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Depressive Disorder, Major, Post Traumatic Stress Disorder
Interventions: yoga, walking; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Bedford, Massachusetts

Search by objective public record fields.

A Study of Adjunctive Aripiprazole in Participants With Major Depressive Disorder

Serum Markers as a Bioassay for Unipolar Depression

The Effects of Psilocybin on Self-Focus and Self-Related Processing in Treatment Resistant MDD

Epidural Cortical Stimulation for Depression

MRI-Guided High-Definition Transcranial Direct Current Stimulation (tDCS) for Depression

Regulation of Affect and Physiology in Depression

Closed-Loop Transcranial Alternating Current Stimulation for the Treatment of Major Depressive Disorder

Dose-Ranging Trial of Creatine Augmentation for Adolescent Females With Treatment-Resistant Major Depressive Disorder

A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

Memantine Plus Es-citalopram in Elderly Depressed Patients With Cognitive Impairment

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

Evaluation of Pharmacogenetic Testing In a Mental Health Population and Economic Outcomes

Effects of Treatment on Decision-making in Major Depression

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use

Pilot Decentralized Trial

Open-Label Psilocybin Study in Transdiagnostic Population

Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation

Self-guided Treatment for Depression

Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder

Brain Imaging for HIV-Associated Thinking and Mood Disorders

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

Identifying Cerebral Hemodynamic Patterns in Mood Disorders and Mild Cognitive Impairment: A Functional Near-Infrared Spectroscopy (fNIRS) Study

A Randomized Control Trial Treating Depression With Yoga and Coherent Breathing Versus Walking in Veterans